Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer.
Patients with stage I and stage II non-small cell lung cancer undergoing complete resection have a 40% to 70% 5-year overall survival despite optimal local therapy. Chemotherapy administered after complete resection has been shown to improve overall survival at 5 years by approximately 5%. This improvement in survival may be confined to patients with stage IB disease 4 cm or greater, and to those with hilar or mediastinal lymph node involvement. The optimal chemotherapy regimen appears to be cisplatin-based doublet or triplet chemotherapy for 3 to 4 cycles. The addition of biologic agents has failed to improve outcomes.
Hematology and Oncology, Meridian Cancer Care, Southern Ocean Medical Center, 1140 Route 72 West, Manahawkin, NJ 08050, USA. Electronic address: enaylor@meridianhealth.com.
Evan C
EC
Naylor
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D009367:Neoplasm Staging; D016896:Treatment Outcome
D002945:Cisplatin
Adjuvant; Chemotherapy; Non–small cell lung cancer